Covers compounds researched for their effects on skin integrity, collagen production, wound healing, hair follicle cycling, and photoprotective pigmentation in research settings.
| Compound | Class | Primary Mechanism | Commonly Reported For | Link |
|---|---|---|---|---|
| GHK-Cu | Copper tripeptide | Activates collagen/elastin synthesis; anti-inflammatory; antioxidant gene expression | Skin aging, wound healing, hair growth | View profile → |
| BPC-157 | Gastric pentadecapeptide | Angiogenesis; growth factor upregulation; tissue repair including dermal | Wound healing, skin repair, scar reduction | View profile → |
| Melanotan II | Cyclic melanocortin peptide | MC1R agonism; melanogenesis stimulation; photoprotective tanning | Skin pigmentation, tanning research | View profile → |
| KPV | α-MSH tripeptide | MC1R/MC3R agonism; anti-inflammatory; wound healing; oral activity reported | Skin inflammation, wound healing, anti-inflammatory | View profile → |
Skin integrity depends on the sustained production of structural proteins — primarily collagen types I and III, and elastin — alongside active remodelling by fibroblasts and keratinocytes. GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide found in human plasma that declines with age. Research has identified it as a pleiotropic signalling molecule capable of upregulating collagen I and III gene expression, stimulating elastin synthesis, and activating antioxidant defence genes including superoxide dismutase and catalase. Copper's role extends beyond chelation: as a cofactor for lysyl oxidase, it is essential for collagen crosslinking and tensile strength. Hair follicle research has investigated GHK-Cu in the context of scalp biology, with preclinical data suggesting it may support follicle cycling and counteract miniaturisation pathways.
BPC-157's relevance to skin and wound research centres on its pro-angiogenic and growth factor-modulating properties. Animal model research has documented accelerated wound closure following topical or subcutaneous BPC-157 administration, attributed to upregulation of vascular endothelial growth factor (VEGF) and enhanced fibroblast migration into wound beds. Angiogenesis — the formation of new capillary networks — is a rate-limiting step in dermal repair, particularly in chronic or poorly vascularised wounds. BPC-157's ability to stimulate this process, alongside modulation of the nitric oxide system, positions it as a subject of interest in both acute wound healing and scar remodelling research. Its preclinical profile spans multiple tissue types, but skin and connective tissue have been among the most studied.
The melanocortin system's role in skin extends from photoprotection to inflammation resolution. Melanotan II drives eumelanin production via MC1R on melanocytes, increasing UV-absorptive pigmentation. KPV — the C-terminal tripeptide of alpha-MSH (Lys-Pro-Val) — retains anti-inflammatory activity through MC1R and MC3R engagement without the full hormonal and arousal side effects of Melanotan II. Research has investigated KPV's ability to inhibit NF-κB-mediated inflammatory signalling in skin and gut epithelium, with oral bioavailability reported in some studies. This makes KPV a subject of interest across dermatological inflammation research and inflammatory bowel disease, where skin and mucosal barriers share mechanistic overlaps.
GHK-Cu is a naturally occurring copper-binding tripeptide (Gly-His-Lys) with a well-characterised research profile in skin biology. It is widely used in cosmetic formulations and has also been studied in subcutaneous injection contexts. Research has identified upregulation of over 30 genes relevant to skin remodelling, including collagen I, III, VI, decorin, and elastin. Hair growth research has investigated GHK-Cu both topically on the scalp and systemically, with preclinical data suggesting effects on follicle density and anagen phase duration. Its safety profile in topical research contexts appears favourable, though systemic dosing data in humans is limited. Commonly reported doses in injection-based research contexts range from 1 mg to 3 mg subcutaneously.
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a protective gastric protein sequence. In wound healing research, both subcutaneous injection near wound sites and topical application in solution have been studied in animal models, with consistent data showing accelerated closure, reduced scarring, and improved tensile strength of healed tissue. Fibroblast migration assays support its direct effect on dermal repair cells. While human clinical trial data for skin-specific applications is limited, the preclinical literature is extensive and mechanistically coherent. Commonly reported doses range from 200 mcg to 500 mcg subcutaneously in research contexts.
Melanotan II's skin application is centred on its potent MC1R agonism, which drives melanogenesis — the production and distribution of eumelanin — in melanocytes. Research has investigated it as a potential photoprotective agent, since eumelanin absorbs UV radiation more effectively than pheomelanin. It is not approved by any regulatory body and has not completed clinical development for any cosmetic or dermatological indication. Reported side effects in research and anecdotal accounts include darkening of existing moles and nevi, which warrants caution, alongside nausea and the central arousal effects described in the libido research context. Its use in tanning research is therefore distinct from therapeutic cosmetic applications.
KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte stimulating hormone (α-MSH) and retains the anti-inflammatory properties of the parent molecule. Research has investigated KPV for inflammatory skin conditions via topical application, as well as for mucosal inflammation via oral administration — an unusual route of activity for a peptide, supported by data suggesting stability in the GI environment and intestinal absorption. NF-κB inhibition is a central mechanism: KPV suppresses pro-inflammatory cytokine production (IL-6, TNF-α) in skin and gut epithelial cells. Its profile overlaps between dermatological inflammation research and IBD research, making it a compound of interest across barrier tissue applications.
Two combination protocols have been noted in anecdotal research discussions for this goal area.
GLOW — a triple regeneration stack combining BPC-157, TB-500, and GHK-Cu. Research has investigated BPC-157 for angiogenesis and wound repair, TB-500 (Thymosin Beta-4) for actin polymerisation and cell migration, and GHK-Cu for collagen gene activation. The combination targets complementary phases of dermal repair: vascular ingrowth, cell motility, and structural protein synthesis. View stack profile at GLOW →
KLOW — an extension of the GLOW stack adding KPV to address the inflammatory component of skin damage and impaired healing. Anecdotal reports suggest the addition of KPV may benefit situations where inflammation is a primary driver of skin breakdown or delayed repair. View stack profile at KLOW →
Research has investigated GHK-Cu via both routes. Topical application is the most common context in cosmetic research — GHK-Cu penetrates skin to some degree and has been used in creams and serums at concentrations typically ranging from 0.1% to 2%. Studies have measured increases in skin density, collagen levels, and reduced fine lines following topical application. Subcutaneous injection has also been used in research settings, theoretically providing higher systemic availability. The relative efficacy of topical versus injectable routes in humans has not been rigorously compared in clinical trials; most published skin data uses topical formulations.
Melanotan II stimulates MC1R receptors on melanocytes, increasing intracellular cAMP and activating the MITF transcription factor — the master regulator of melanogenesis. This drives increased eumelanin synthesis and dispersion, producing visible darkening even in the absence of UV exposure. Its regulatory status is relevant because it is not approved in any jurisdiction, meaning it lacks the safety evaluation, standardised manufacturing, and clinical oversight associated with licensed medicines. Reported side effects in research and anecdotal accounts include mole darkening, nausea, facial flushing, and spontaneous arousal — and the long-term implications of MC1R over-stimulation, particularly regarding nevi changes, are not fully characterised in clinical populations.
GHK-Cu and KPV are both tripeptides but act via entirely different mechanisms and are researched for different primary outcomes. GHK-Cu functions as a tissue-remodelling signal, upregulating collagen, elastin, and antioxidant genes through copper-dependent and receptor-mediated pathways. KPV operates as an anti-inflammatory agent via MC1R/MC3R agonism, suppressing NF-κB-driven cytokine production. In practical research terms, GHK-Cu is more relevant to structural skin quality — wrinkles, firmness, wound repair scaffolding — while KPV is more relevant to inflammatory skin conditions where cytokine dysregulation drives tissue damage. They are not interchangeable and may be studied in combination for conditions where both inflammation and structural repair are relevant.
Preclinical research has used both topical and subcutaneous routes for BPC-157 in wound healing studies. Topical application — typically in saline solution applied directly to wound surfaces in animal models — has shown efficacy in accelerating closure and improving healing quality. Subcutaneous injection near the wound site has also been studied and appears to produce comparable or superior outcomes in some models. The relative bioavailability and activity of topical versus injectable BPC-157 in human skin has not been established in clinical trials. Researchers reviewing this compound for dermal applications will find the majority of published data originates from rodent wound models using one or both administration routes.